Reversible male contraception by targeted inhibition of serine/threonine kinase 33

Angela F. Ku,Kiran L. Sharma,Hai Minh Ta,Courtney M. Sutton,Kurt M. Bohren,Yong Wang,Srinivas Chamakuri,Ruihong Chen,John M. Hakenjos,Ravikumar Jimmidi,Katarzyna Kent,Feng Li,Jian-Yuan Li,Lang Ma,Chandrashekhar Madasu,Murugesan Palaniappan,Stephen S. Palmer,Xuan Qin,Matthew B. Robers,Banumathi Sankaran,Zhi Tan,Yasmin M. Vasquez,Jian Wang,Jennifer Wilkinson,Zhifeng Yu,Qiuji Ye,Damian W. Young,Mingxing Teng,Choel Kim,Martin M. Matzuk
DOI: https://doi.org/10.1126/science.adl2688
IF: 56.9
2024-05-25
Science
Abstract:Men or mice with homozygous serine/threonine kinase 33 ( STK33 ) mutations are sterile owing to defective sperm morphology and motility. To chemically evaluate STK33 for male contraception with STK33-specific inhibitors, we screened our multibillion-compound collection of DNA-encoded chemical libraries, uncovered potent STK33-specific inhibitors, determined the STK33 kinase domain structure bound with a truncated hit CDD-2211, and generated an optimized hit CDD-2807 that demonstrates nanomolar cellular potency (half-maximal inhibitory concentration = 9.2 nanomolar) and favorable metabolic stability. In mice, CDD-2807 exhibited no toxicity, efficiently crossed the blood-testis barrier, did not accumulate in brain, and induced a reversible contraceptive effect that phenocopied genetic STK33 perturbations without altering testis size. Thus, STK33 is a chemically validated, nonhormonal contraceptive target, and CDD-2807 is an effective tool compound.
multidisciplinary sciences
What problem does this paper attempt to address?